Research
GSK's $10.6 Billion Nashville: Why the Nuvalent Multiple Just Reset the Patent-Cliff Math for Every Major Drugmaker
John Grey — Healthcare & longevity desk On the morning the markets were busy pricing a US-Iran ceasefire and a Federal Reserve hold, GSK’s new chief executive wrote the largest cheque of his tenure for a Cambridge, Massachusetts biotech that has yet to generate a single dollar of commercial